Dr. Levy on EGFR TKIs in Lung Cancer

Benjamin P. Levy, MD
Published: Monday, Nov 09, 2015



Benjamin P. Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

More agents have been approved in the field for patients with EGFR mutations within the past year, Levy explains, such as gefitinib. Prior to such approvals, treatment choices included erlotinib and afatinib. The combination of erlotinib plus bevacizumab is also being investigated in an ongoing US study.

There are also third-generation TKIs previously used for resistant disease that are now being studied in the frontline setting, Levy says.

<<< View more from the 2015 NY Lung Cancer Symposium



Benjamin P. Levy, MD, medical director, Thoracic Oncology, Mount Sinai Health System, discusses EGFR TKIs for the treatment of patients with lung cancer.

More agents have been approved in the field for patients with EGFR mutations within the past year, Levy explains, such as gefitinib. Prior to such approvals, treatment choices included erlotinib and afatinib. The combination of erlotinib plus bevacizumab is also being investigated in an ongoing US study.

There are also third-generation TKIs previously used for resistant disease that are now being studied in the frontline setting, Levy says.

<<< View more from the 2015 NY Lung Cancer Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x